Statins decrease mortality in Lebanese patients with sepsis: A multicenter study

Main Article Content

Rola Ajrouche
Amal Al-Hajje
Nancy El-Helou
Sanaa Awada
Samar Rachidi
Salam Zein
Pascale Salameh


Sepsis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mortality, Survival Analysis, Lebanon


Background: Sepsis is a significant public health concern. The clinical response to statins is variable among sepsis patients.

Objective: The aim of the study was to determinate the effect of statin-treatment on mortality in Lebanese patients with sepsis.

Methods: A retrospective multicenter study on Lebanese patients with sepsis between January 2008 and March 2012 was conducted. Patients with a primary diagnosis of sepsis admitted to the intensive care unit of two tertiary care hospitals in Beirut were included. Patients who continued to receive statin therapy for dyslipidemia during the hospital course were included in the statin treatment group. The control group consisted of patients not taking statin. Demographic characteristics, clinical signs, standard laboratory test and treatment received were compared between these two groups using univariate analysis. Logistic regression and survival analysis were performed by SPSS.

Results: Three hundred fifty one Lebanese patients were included (age: 71.33 SD=14.97 years; Male: 56%). Among them, 30% took a statin at the doses recommended for dyslipidemia. The comparison of the two groups showed that in the statin treatment group: The mean serum level of C-reactive protein at the time of sepsis was significantly decreased (P=0.050), the length-stay at ICU significantly increased (P=0.047) and mortality significantly reduced (P<0.001). Results were confirmed by logistic regression, particularly for mortality. In the Cox regression analysis, hypothermia and shock were significantly associated with high mortality while statin treatment decreased mortality (hazard ratio = 0.540; 95% CI: 0.302-0.964; P=0.037).

Conclusion: At usual doses for dyslipidemia, statin treatment decreased incidence of mortality related to sepsis and improved the survival in this Lebanese septic population. Large randomized controlled clinical trials must be realized to give conclusive results about the potential beneficial effect of statins in sepsis.

Abstract 2819 | PDF Downloads 985


1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-353.

2. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-1402.

3. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, Wüthrich RP, Ammann P. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004;175(1):83-90.

4. Merx M, Weber C. Statins in the intensive care unit. Curr Opin Crit Care. 2006;12(4):309-314.

5. McGown C, Brookes Z. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth. 2007;98(2):163-175.

6. Zhang J, Cheng X, Liao YH, Lu B, Yang Y, Li B, Ge H, Wang M, Liu Y, Guo Z, Zhang L. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther. 2005;19(1):13-21.

7. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687-692.

8. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-1012.

9. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413-418.

10. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.

11. Martin CP, Talbert RL, Burgess DS, Peters JI.. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy. 2007;27(1):20-26.

12. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34(4):1080-1086.

13. Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, Wu CC. Statins do not improve short term survival in an oriental population with sepsis. Am J Emerg Med. 2007;25(5):494-501.

14. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med. 2006;32(1):160-164.

15. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001;88(4):347-352.

16. American College of Chest Physicians: Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.

17. Ribera MC, Pascual R, Orozco D, Pérez Barba C, Pedrera V, Gil V. Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis. 2006;25(6):389-393.

18. Hooper D. Quinolones. In: Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, Bennett's. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:404-423.

19. Cox CE, Corrado ML. Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections. Am J Med. 1985;78(6A):92-94.

20. Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Feingold KR. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect. 1998;121(2):335-347.

21. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000;294(3):1043-1046.

22. Yasuda H, Yuen P, Hu X, Zhou H, Star R. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006;69(9):1535-1542.

23. Kruger P, Freir N, Venkatesh B, Robertson T, Roberts M, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med. 2009;35(4):717-721. doi: 10.1007/s00134-008-1358-3.

24. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(5):1545-1550.

25. Jones P. Comparing HMG-CoA reductase inhibitors. Clin Cardiol. 2003;26(1 Suppl 1):I15-I20.

26. Kajinami K, Akao H, Polisecki E, Schaefer EJ. Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005;96(9A):65K-70K;

27. Wang C, Liu P, Liao J. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44.

28. Coimbra M, Banciu M, Fens MH, de Smet L, Cabaj M, Metselaar JM, Storm G, Schiffelers RM. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release. 2010;148(3):303-310. doi: 10.1016/j.jconrel.2010.09.011.

Most read articles by the same author(s)

1 2 > >>